Sara M. Tolaney, MD, MPH

Chief of the Division of Breast Oncology
Dana-Farber Cancer Institute;
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Authored Items

monarchE and NATALEE: Key Outcomes in HR-Positive/HER2-Negative Early Breast Cancer
By Sara M. Tolaney, MD, MPH
European Society for Medical Oncology (ESMO)
ESMO 2025 - Early Breast Cancer
In this video, Dr Sara Tolaney underscores the positive overall survival outcomes from the monarchE trial, reinforcing the impact of adjuvant abemaciclib plus endocrine therapy in high-risk, hormone receptor (HR)-positive/HER2-negative early breast cancer, while also noting the sustained 5-year benefits observed with ribociclib and nonsteroidal aromatase inhibitors in the NATALEE trial. Read More ›


© Amplity, Inc. All Rights Reserved. Privacy Policy